Target Validation Information
TTD ID	T58449
Target Name	Cyclin-dependent kinase 7 (CDK7)
Type of Target	Clinical trial
Drug Potency against Target	Flavopiridol	Drug Info	IC50 = 110~300 nM	[3]
	R-roscovitine	Drug Info	Ki = 540 nM	[4]
	R547	Drug Info	IC50 = 1~3 nM	[3]
	SNS-032	Drug Info	Ki = 62 nM	[2]
	ZK 304709	Drug Info	IC50 = 85 nM	[3]
	2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	Drug Info	IC50 = 800 nM
	PF-228	Drug Info	IC50 = 197 nM	[1]
Action against Disease Model	ZK 304709	Drug Info	Blocked growth of h uMan t uMour cell lines at IC50 = 317 nM, by inducing a dose-dependent G1-S arrest followed by apoptosis. Superior efficacy over standard chemotherapy in h uMan t uMour xenografts and orthotopic mouse models of h uMan pancreatic cancer.	[3]
References
REF 1	Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
REF 2	2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo. Br J Pharmacol. 1996 Nov;119(6):1101-8.
REF 3	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
REF 4	A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. J Med Chem. 2010 Dec 23;53(24):8508-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.